Venous Thrombosis After Removal of Central Venous Catheter
Launched by MEIR MEDICAL CENTER · Mar 31, 2024
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the occurrence of blood clots (thrombosis) that may develop at the sites where central venous catheters (thin tubes used to deliver medications or fluids) are inserted, after these catheters are removed. The researchers want to find out how many patients experience this issue and if certain catheter insertion sites are more likely to develop thrombosis than others. They also aim to identify any characteristics that might predict the risk of developing these blood clots.
To participate in this study, patients must be admitted to the intensive care unit and have had a central catheter placed and then removed during their hospital stay. Unfortunately, those who had their catheter inserted or removed outside the ICU, or who were on full anticoagulation (blood-thinning) treatment while in the ICU, won't be eligible. Participants can expect to undergo careful monitoring after the removal of their catheter to check for any signs of thrombosis. The findings from this trial could help improve patient care by providing better guidance on monitoring and treatment after catheter removal.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Patients who were admitted to the intensive care unit and had a central catheter inserted during their stay in the unit for any reason, and whose central catheter was removed during their stay in the general intensive care unit.
- • -
- • Exclusion Criteria:Patients whose insertion or removal of the central catheter did not occur during the hospitalization in the intensive care unit, patients who were treated with full anticoagulation in the intensive care unit.
- • -
About Meir Medical Center
Meir Medical Center is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. As a prominent sponsor of clinical studies, Meir Medical Center is committed to fostering collaboration among healthcare professionals, researchers, and patients to explore new therapies and treatment modalities. With a focus on ethical practices and patient safety, the center aims to contribute significantly to the scientific community while enhancing the quality of care provided to its diverse patient population. Through its robust infrastructure and multidisciplinary approach, Meir Medical Center stands at the forefront of medical innovation, driving progress in various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kfar Saba, Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported